[HTML][HTML] Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor
AN Bullock, S Russo, A Amos, N Pagano, H Bregman… - PloS one, 2009 - journals.plos.org
PloS one, 2009•journals.plos.org
Background The serine/threonine kinase PIM2 is highly expressed in human leukemia and
lymphomas and has been shown to positively regulate survival and proliferation of tumor
cells. Its diverse ATP site makes PIM2 a promising target for the development of anticancer
agents. To date our knowledge of catalytic domain structures of the PIM kinase family is
limited to PIM1 which has been extensively studied and which shares about 50% sequence
identity with PIM2. Principal Findings Here we determined the crystal structure of PIM2 in …
lymphomas and has been shown to positively regulate survival and proliferation of tumor
cells. Its diverse ATP site makes PIM2 a promising target for the development of anticancer
agents. To date our knowledge of catalytic domain structures of the PIM kinase family is
limited to PIM1 which has been extensively studied and which shares about 50% sequence
identity with PIM2. Principal Findings Here we determined the crystal structure of PIM2 in …
Background
The serine/threonine kinase PIM2 is highly expressed in human leukemia and lymphomas and has been shown to positively regulate survival and proliferation of tumor cells. Its diverse ATP site makes PIM2 a promising target for the development of anticancer agents. To date our knowledge of catalytic domain structures of the PIM kinase family is limited to PIM1 which has been extensively studied and which shares about 50% sequence identity with PIM2.
Principal Findings
Here we determined the crystal structure of PIM2 in complex with an organoruthenium complex (inhibition in sub-nanomolar level). Due to its extraordinary shape complementarity this stable organometallic compound is a highly potent inhibitor of PIM kinases.
Significance
The structure of PIM2 revealed several differences to PIM1 which may be explored further to generate isoform selective inhibitors. It has also demonstrated how an organometallic inhibitor can be adapted to the binding site of protein kinases to generate highly potent inhibitors.
Enhanced version
This article can also be viewed as an enhanced version in which the text of the article is integrated with interactive 3D representations and animated transitions. Please note that a web plugin is required to access this enhanced functionality. Instructions for the installation and use of the web plugin are available in Text S1.
PLOS